## **Claims**

1. A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof.

5

10

2. A combination according to claim 1 wherein the endothelin receptor antagonist is selected from A-127722, atrasentan (ABT-627), BQ-123, BQ-788, BMS 182874, feloprentan, BSF 420627, FR139317, IPI-950, L-749,329, L-754,142, LU 110896, LU 110897, PD 156707, PD 155080, Ro 46-2005, bosentan (Ro 47-0203), SB 217242, SB 209670, TAK-044, YM598, sitaxsentan (TBC11251), ambrisentan, tezosentan, darusentan, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide, ZD1611 and N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054), or a pharmaceutically acceptable

15

20

25

salt thereof.

3. A combination according to claim 1 or 2 wherein the EGFR TKI is selected from: *N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (ZD1839);

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, or a pharmaceutically-acceptable salt thereof (linked to the code numbers CP 358774 and OSI-774 (the monomethanesulphonate salt));

6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (linked to the code numbers PD 183805 and CI 1033);

4-[(1R)-1-phenylethylamino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine (linked to the code numbers PKI-166, CGP 75166 and CGP 59326);

N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide (linked to the code numbers CL-387785 and EKB-785); and

4-(3-chloro-4-fluoroanilino)-3-cyano-6-(4-dimethylaminobut-2(E)-enamido)-7-ethoxyquinoline (EKB-569);

or a pharmaceutically acceptable salt thereof.

- 4. A combination according to any one of claims 1-3 wherein the endothelin receptor antagonist is selected from ZD4054, or a pharmaceutically acceptable salt thereof, and the EGFR TKI is selected from ZD1839, or a pharmaceutically acceptable salt thereof.
- 5 5. A combination according to any one of claims 1-4 for use as a medicament.
  - 6. A pharmaceutical composition comprising a combination according to any one of claims 1-4, in association with a pharmaceutically acceptable diluent or carrier.
- 7. A method of treating cancer, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a combination according to any one of claims 1-4.
- 8. The use of a combination according to claims 1-4, in the manufacture of a medicament for use in the treatment of cancer, in a warm-blooded animal, such as man.
  - 9. A combination comprising a combination according to claims 1-4, for use in the treatment of cancer.
- 20 10. The method or use or combination according to claims 7-9 wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, brain cancer, renal cancer, lymphoma and leukaemia.
  - 11. The use of the combination according to claims 1-4, in the manufacture of a medicament for use in the production of an anti-angiogenic effect, in a warm-blooded animal, such as man.
  - 12. The method or use or combination according to claim 10 wherein the cancer is prostate cancer.

30

- 13. The method or use or combination according to claim 10 wherein the cancer is NSCLC.
- 14. The method or use or combination according to claim 10 wherein the cancer is in a5 metastatic state.
  - 15. The method or use or combination according to claim 10 wherein the cancer is in a non-metastatic state.
- 10 16. The method or use or combination according to claim 10 wherein the cancer is renal, thyroid, lung, breast or prostate cancer that is producing bone metastases.